Abstract:Background: Numbers of HIV latency reversal agents (LRAs) have been tested in clinical trials, but with limited effect. EK-16A is an ingenol derivative that isolated from Euphorbia kansui. Our prior studies have suggested that it could reactivate latent HIV and meanwhile inhibit HIV infection in vitro. Here, we further advanced the research in vivo. Methods: In vitro, the activity of EK-16A liposomes was measured in HIV latently infected cells. In serum pharmacology test, BALB/c mice were orally administered with EK-16A liposomes, serum was separated and co-cultured with cells, HIV reactivation was measured. In vivo, NSG mice were transplanted with human cells for 3 weeks and then administered with EK-16A liposomes for 3 days. In ACH2 cell engrafted NSG mice, P24 in plasma and cell-associated HIV RNA in tissues was measured. In J-Lat 10.6 cell engrafted NSG mice, GFP expression of J-Lat 10.6 cells in diverse tissues was measured. Hematoxylin and eosin (HE) staining was carried out for histopathological examination in both mice. Results: EK-16A liposomes can reactivate latent HIV in ACH2 and J-Lat 10.6 cells. Serum pharmacological test showed that EK-16A retained activity after oral administration. Importantly, in ACH2 cell engrafted NSG mice, EK-16A liposomes increased the secretion of P24 in plasma and the expression of cell-associated HIV RNA in tissues. In J-Lat 10.6 cell engrafted NSG mice, EK-16A liposomes increased the GFP expression of J-Lat 10.6 cells in diverse tissues, including the bone marrow, spleen, liver, lung and peripheral blood. Furthermore, there was no obvious histopathological change associated with the use of EK-16A liposomes in both mice. Conclusions: Our results confirmed the enhancing HIV replication activity and preliminary security of EK-16A in human cell engrafted NSG mice, laying the foundation for research in clinical trials.

Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui

Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections

Research progress on HIV latency-reversing agents and its mechanism

Dilazep Synergistically Reactivates Latent HIV-1 in Latently Infected Cells.

Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency

Effective in vivo reactivation of HIV-1 latency reservoir via oral administration of EK-16A-SNEDDS

A Chalcone Derivative Reactivates Latent HIV-1 Transcription Through Activating P-TEFb and Promoting Tat-SEC Interaction on Viral Promoter.

EK-16A Liposomes Enhance HIV Replication in ACH2 or J-Lat 10.6 Cell Engrafted NSG Mice

Specific Reactivation of Latent HIV-1 with Designer Zinc-Finger Transcription Factors Targeting the HIV-1 5′-LTR Promoter

Design, synthesis, and biological evaluation of AV6 derivatives as novel dual reactivators of latent HIV-1

Pharmacological suppression of glycogen synthase kinase-3 reactivates HIV-1 from latency via activating Wnt/beta-catenin/TCF1 axis in CD4(+) T cells

Thiostrepton Reactivates Latent HIV-1 Through the P-Tefb and NF-κB Pathways Mediated by Heat Shock Response

BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency

Novel Aptamers for the Reactivation of Latent HIV

A Natural Product From Polygonum Cuspidatum Sieb. Et Zucc. Promotes Tat-Dependent Hiv Latency Reversal Through Triggering P-Tefb'S Release From 7sk Snrnp

Euphorbia fischeriana extract reactivates latent HIV through nuclear factor-κB pathway

Quercetin Synergistically Reactivates Human Immunodeficiency Virus Type 1 Latency by Activating Nuclear Factor‑κb.

Resveratrol Promotes HIV-1 Tat Accumulation via AKT/FOXO1 Signal-ing Axis and Potentiates Vorinostat to Antagonize HIV-1 Latency

A Novel Bromodomain Inhibitor Reverses HIV-1 Latency Through Specific Binding with BRD4 to Promote Tat and P-TEFb Association.

Progress and Challenges in the Use of Latent HIV-1 Reactivating Agents

A novel bromodomain inhibitor, CPI-203, serves as an HIV-1 latency-reversing agent by activating positive transcription elongation factor b.